溴尿嘧啶
BET抑制剂
癌症
癌症研究
医学
三阴性乳腺癌
乳腺癌
表观遗传学
前列腺癌
结直肠癌
奶油
转移
药理学
转录因子
生物
内科学
生物化学
基因
作者
Francis Joseph Giles,Michael Witcher,Bill Brown
标识
DOI:10.1093/annonc/mdy279.416
摘要
Background: The Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins are key regulators of epigenetic control. Modulation of the BET family is a developmental therapeutics priority. Cyclic AMP response element binding protein (CREB)-binding protein (CBP) and E1A interacting protein of 300kDa (EP300 or P300) are highly homologous BRD-containing transcriptional co-activators and are validated oncology targets. We have developed a series of potent dual inhibititors of BET-CBP/P300 with NEO2734 and NEO1132 as lead clinical candidates.
科研通智能强力驱动
Strongly Powered by AbleSci AI